Circulating Tumor Cell γH2AX Immunofluorescence Assay

NCI Publications

A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas


Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas


Histone γH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers


Monitoring drug-induced γH2AX as a pharmacodynamic biomarker in individual circulating tumor cells


Use of circulating tumor cells to monitor pharmacodynamic responses of patients in early stage clinical trials